Patients beginning lung cancer treatment demonstrated a high prevalence of atherosclerosis, which suggests that they may benefit from calcium scoring, new data showed. According to a presentation ...
Credit: Getty Images. NXC-201 is an autologous BCMA-targeted investigational chimeric antigen receptor T cell therapy. The Food and Drug Administration (FDA) has granted Orphan Drug designation to NXC ...
AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain (AL) amyloidosis in two Phase III trials. A light chain depleter antibody, anselamimab was being investigated in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback